BioCentury on BioBusiness,
Epigenetics: Epizyme-Celgene, Constellation-Genentech reflect different goals
Monday, April 30, 2012
A large epigenetics deal announced last week between Epizyme
Inc. and Celgene
Corp. has many similarities with January's deal between Constellation
Pharmaceuticals Inc. and Genentech
Inc. But the pacts are structured differently because the smaller
biotechs have different goals.
Epizyme is set up to remain
independent and commercialize its own products in the U.S., although the deal
has elements that could ease an acquisition by partner Celgene. In contrast,
Constellation's deal has set the company up to be acquired, with elements to
ensure some upside if Genentech does not exercise its call option (see
BioCentury, Jan. 23).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
If you are a current subscriber, log in below or in the upper right corner of this
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]